Genomic and proteomic technologies for individualisation and improvement of cancer treatment.
The development of microarray-based technologies for characterising tumours, both at the genomic and proteomic levels, has had a significant impact on the field of oncology. Gene expression profiling of various human tumour tissues has led to the identification of expression patterns related to disease outcome and drug resistance, as well as to the discovery of new therapeutic targets and insights into disease pathogenesis. Protein microarray technologies, such as reverse-phase protein arrays, provide the unique opportunity to profile tissues and assess the activity of signalling pathways within isolated cell populations. This technology can be used to identify patients likely to benefit from specific treatment modalities and also to monitor therapeutic response in samples obtained during and after treatment. Routine application of genomic and proteomic microarray technologies in clinical practice will require significant efforts to standardise the techniques, controls and reference standards, and analytical tools used. Extensive, independent validation using large, statistically-powered datasets will also be necessary. Inclusion of concomitant genomic and proteomic-based molecular profiling techniques into clinical trial protocols will bring us closer to the reality of patient-tailored therapy.
Wulfkuhle
Julia
J
NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. wulfkuhle@cber.fda.gov
Espina
Virginia
V
Liotta
Lance
L
Petricoin
Emanuel
E
D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D040081:Protein Array Analysis; D020543:Proteome / Q000235:genetics*; D040901:Proteomics / Q000379:methods*
D020543:Proteome